The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook

Mingyao Luo1, Mingyuan Du2,3, Chang Shu1,2,3

  • 1State Key Laboratory of Cardiovascular Diseases, Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Frontiers in Pharmacology
|November 5, 2021
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in pulmonary embolism (PE) pathogenesis. This review highlights their potential as diagnostic biomarkers and therapeutic targets for PE, improving patient outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Pulmonary embolism (PE) is a severe condition linked to deep venous thrombosis, potentially causing fatal cardiopulmonary suppression and chronic respiratory dysfunction.
  • MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally by targeting messenger RNAs (mRNAs).

Purpose of the Study:

  • To review the current literature on the functions and downstream mechanisms of miRNAs in the context of PE.
  • To explore the potential of miRNAs as biomarkers and therapeutic targets for PE.

Main Methods:

  • Literature review of studies on miRNA functions, mechanisms, and targetomes in PE and venous thrombophilia.
  • Analysis of miRNA roles in PE pathogenesis and clinical applications.

Main Results:

  • miRNAs are implicated in the mechanisms and progression of PE.
  • Current research indicates miRNAs can serve as biomarkers for PE diagnosis and prognosis.
  • miRNAs show promise as novel therapeutic targets for PE treatment.

Conclusions:

  • Various miRNAs play significant roles in PE, offering potential as therapeutic targets.
  • Combined miRNA biomarkers or miRNA signatures could enhance PE prediction.
  • Development of miRNA-targeted therapies is crucial for advancing PE treatment alongside conventional methods.

Related Concept Videos

Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
182
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
70
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
75